Dechra Just Closed the Diagnostic Side of Canine Cushing's

Hyperadrenocorticism is one of the more common endocrine diseases in older dogs, with population-level prevalence reported above 1 in 100 in the 2012 ACVIM consensus statement. For the past 25 years U.S. veterinarians have diagnosed it using a human-labeled drug pulled off-label, with no canine dosing data, no veterinary supply guarantee, and recurring shortage scares. That ended this morning. Dechra announced FDA approval of CosACTHen (cosyntropin injection) on May 19, 2026 as the first and only cosyntropin product approved specifically for canine patients. The approval makes Dechra the only animal-health company carrying both the labeled diagnostic and the labeled treatment for the most common endocrine disease in older dogs.

Dechra wins FDA approval for first canine-labeled cosyntropin

The FDA's Center for Veterinary Medicine approved CosACTHen via the traditional new animal drug application pathway, not the expanded conditional approval lane that has dominated specialty veterinary pharma launches over the past two years. The indication: stimulation of cortisol secretion in dogs as part of the ACTH stimulation test, the standard diagnostic for both Cushing's disease (hyperadrenocorticism) and Addison's disease (hypoadrenocorticism).

Cosyntropin is a synthetic ACTH analog that has been a clinical staple in veterinary endocrinology for decades. Until today, every ACTH stim test run in a U.S. veterinary practice used either Cortrosyn (Amphastar's human-labeled cosyntropin product) prescribed off-label, or compounded cosyntropin sourced through veterinary compounding pharmacies like Wedgewood and Roadrunner.

The off-label and compounded supply chain has been chronically unstable. Cortrosyn has carried an active ASHP drug shortage record since January 2019, and as the only commercial ACTH product available in the U.S., any disruption pushes practices into reliance on compounded product and, in some periods, into delayed or canceled testing.

Dechra Pharmaceuticals, taken private by EQT and the Abu Dhabi Investment Authority in a £4.46B deal that closed in January 2024, already owns the dominant labeled treatment for canine Cushing's: Vetoryl (trilostane), approved by FDA in 2008. With CosACTHen, the company now controls both ends of the canine Cushing's clinical workflow with FDA-labeled products.

Why owning the Cushing's workflow end to end matters more than the approval

The reframing here is bigger than a single approval. The pattern that has reshaped veterinary specialty pharma over the last decade is the diagnose-plus-treat bundle. Zoetis built Apoquel and Cytopoint into an integrated dermatology franchise. Elanco followed with Zenrelia and now Befrena. CosACTHen and Vetoryl are the endocrine version of that play.

When a senior dog presents with clinical signs of Cushing's, the workflow now runs through one supplier from screening test to lifetime maintenance therapy. Detailing reps will bundle the conversation, and practice protocols built around a single supplier's continuing-education and rebate structure tend to stick.

The supply chain risk leaves the practice and lands on the manufacturer. Compounded cosyntropin sits in a gray zone that practice owners have learned to manage with workarounds. FDA-overseen production, lot-level traceability, and a manufacturer with commercial incentive to keep dogs on test is a different procurement equation. Practice managers should expect their distribution reps at Patterson Veterinary, Covetrus, and Henry Schein Animal Health to push CosACTHen onto formulary fast.

Veterinary compounders have built durable revenue lines on the back of human-product supply gaps and species-specific dosing demands. CosACTHen takes the largest of those ACTH lines and converts it to a labeled product. Wedgewood, Roadrunner, and the regional compounders that have served as the bridge supply will see ACTH volume migrate over the next 12 to 18 months. The bigger strategic question is which other long-running compounded standards follow the same path next. Pegasus Laboratories' Liavium-CA1, which received FDA conditional approval on May 18 for canine neuropathic pain, is the other example from the same 72-hour window. Both products formalize long-running off-label clinical standards into labeled veterinary products. The cadence is new.

The Vetoryl franchise also gets defended on the diagnostic side. Vetoryl is well past its 2009 U.S. exclusivity window and operates in a more competitive trilostane market than it did at launch. Anchoring the upstream diagnostic with a labeled product is a defensive move that keeps clinics inside the Dechra commercial relationship even as the treatment side commoditizes.

What pricing, distribution, and the compounder response will tell us next

An ACTH stim test currently runs roughly $150 to $300 to the pet owner, with the cosyntropin reagent the most variable cost line inside that. The CosACTHen list price and rebate structure relative to compounded and human-Cortrosyn sourcing determines how fast clinics convert. Dechra reps will lean on supply reliability and labeling rather than headline price. Watch whether distributors land contracts that close the gap.

Wedgewood, in particular, has been repositioning its veterinary book toward higher-margin compounded therapeutics ahead of FDA's evolving GFI #256 framework on animal drug compounding. If CosACTHen converts the ACTH stim volume away from compounding within a year, expect Wedgewood and Roadrunner to accelerate their own pivot toward indications where labeled product is structurally less feasible.

Hyperadrenocorticism is rare in cats and the ACTH stim test is run far less often, but the population of screened feline patients is non-trivial. A feline label extension is the obvious incremental move, and the timing tells you how Dechra prioritizes line-extension capital under EQT ownership.

Mars Veterinary Health (Banfield, BluePearl, VCA), NVA, Pathway Vet Alliance, and AmeriVet collectively run the testing and treatment protocol decisions for thousands of clinic locations. Watch which corporate groups standardize on CosACTHen first. The volume those decisions move is what determines whether this approval is a meaningful Vetoryl-franchise defense or a marginal one.

Source: Dechra company-announcement via PR Newswire, May 19, 2026.